Objective To study the efficacy and safety of cytokine-induced killer cells(CIK cells) combined with chemotherapy in treating advanced retinoblastoma(RB). Methods Thirty child patients with RB at stage D were enrolled for the study. 15 patients received chemotherapy (control group) while the rest were treated with CIK cells infusion combined with chemotherapy (study group), from whom 10-35 ml autologous peripheral blood was taken before chemotherapy to culture CIK cells in vitro for about 10 days. CIK cells were reinfused every other day three times. The vital signs in the process of cell reinfusion were observed. Changes of peripheral blood indexes, biochemical indexes, immunity indexes, life quality and side effects were also monitored four weeks after the reinfusion. Results (1) CIK cells reinfusion was safe. 15 patients received a total of 46 cycles of CIK cells therapy. Vital signs of all the children were stable. During the 46 courses (138 times) of CIK cells reinfusion, only three cases of patients had a fever during the first 24 hours. No patients had any allergic reactions. With regard to liver and kidney functions and cardiac enzymes, no obvious difference was observed before and after the reinfusion. (2) During the follow-up period, the efficiency and disease control rate in the study group (73.3%, 93.3%) seemed to be higher than that in the control group (67.7%, 80%),but not significantly different. There was improvement in physical strength, appetite and immunity indexes（P＜0.05）in the study group. The change in the ratio of CD4+CD25+ T cells was significant. Conclusions The autologous CIK cell therapy is safe，which improves clinical symptoms significantly in patients with RB.
Key words
CIK cells /
advanced retinoblastoma /
therapy
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
［1］ 刘秋玲. 儿童恶性肿瘤治疗新策略［J］. 武警医学，2010，21（8）：645-648.
［2］ Schmidt-Wolf I G, Lefterova P, Mehta B A, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine -induced killer cells ［J］. Exp Hematol, 1993,21(13):1673-1679.
［3］ Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells(IRCC) ［J］. J Cancer Res Clin Oncol, 2011,137(2):305-310.
［4］ Linn M A. Intraocular retinoblastoma: the case for a new group classification ［J］. Ophthalmol Clin North Am, 2005,18:41-53.
［5］ Therasse P, Arbuck S G, Eisenhauer E A, et al. New guidelines to evaluate the response to treatment in solid tumors ［J］. JNCI, 2000,92:205-216.
［6］ 鲍萍萍，郑 莹，王春芳，等．2002-2004年上海市儿童恶性肿瘤发病特征［J］．中国肿瘤，2009，18(2)：119-120．
［7］ Baas P, Belderbos J S. Chemoradiation therapy in non small cell lung cancer ［J］. Cur rent Opinion in Oncology, 2011, 23(2):140-149.
［8］ Blattman J N, Greenberg P D. Cancer immunotherapy: a treatment for the masses ［J］. Science, 2004, 305(5681): 200-205.
［9］ 姚 春，宋善俊. 脐血CIK细胞对耐药白血病细胞体外杀伤效应及其机制的研究［J］. 临床血液学杂志，2008，21(7):369-372.
［10］ 刘 苗，吴小艳，金润铭. 细胞因子诱导的杀伤细胞生物活性及杀瘤机制［J］. 实用儿科临床杂志，2009，24(15):1163-1166.
［11］ Pievani A, Borleri G, Pende D, et al. Dual-functional capability of CD3+ CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR- mediated specific cytotoxicity［J］. Blood, 2011,118(12):3301-3310.
［12］ Li J J, Gu M F, Pan K, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma［J］. J Immunother, 2012, 35(2):189-195.
［13］ Luo H, Zhou X. Researche advances on CIK cells and their clinical use in lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2011, 14(12):954-959.
［14］ Titov K S, Gritsa A N, Kiselevski M V ,et al. Biotherapy of malignant peritoneal effusions in ovarian carcinoma［J］. Vopr Onkol, 2011,57(4):470-474.
［15］ 张乐萍，陆爱东，童春容，等. 细胞因子诱导的杀伤细胞/白细胞介素-2治疗儿童急性淋巴细胞白血病微小残留病疗效观察［J］. 实用儿科临床杂志，2003，18（3）：185-186.
［16］ Zanussi S, Vaccher E, Caffau C, et al. Interferon-gamma secretion and Perforin expression are impaired in CD+8T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type ［J］. Cancer Immunol Immunother , 2003, 52: 28-32.
［17］ 张世文，何晓光，李晓江，等. 自体CIK 细胞治疗对喉癌患者放疗后免疫功能的影响［J］. 临床耳鼻喉头颈外科杂志，2011，25（2）：61-63.
［18］ 周炳喜.细胞因子诱导杀伤细胞（CIK 细胞）在消化道癌中的疗效观察［J］. 现代预防医学，2011，38（16）:3335-3336.
［19］ 陈复兴，刘军权，张南征，等. 自身细胞因子诱导的杀伤细胞过继性免疫治疗恶性肿瘤的临床观察［J］. 癌症，2002，21（7）:797-801.
［20］ 于 渊，李 岩，荣风年，等. 自体CIK细胞治疗对卵巢癌调节性T细胞的影响［J］. 山东大学学报（医学版），2010，48（5）:101-104.
PDF(773 KB)
